Who owns Cardiff Oncology, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of CRDF from SEC Form 13F filings across 75 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 75 institutions disclosed 18.0M shares of Cardiff Oncology, Inc. worth $21.4M — about 23.6% of shares outstanding; the largest disclosed holder is Laurion Capital Management LP. Source: SEC Form 13F filings, parsed by EvidInvest.
75
13F holders
$21.4M
value, 2026 filers
23.6%
of shares outstanding (18.0M sh)
2
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of CRDF's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Laurion Capital Management LP | 3.1M | $3.7M | 0.1% | 4.1% | 0.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $3.5M | 0.0% | 3.8% | -1.0% |
| 3 | Pfizer Inc | 2.4M | $3.0M | 1.8% | 3.2% | 0.0% |
| 4 | FRANKLIN TEMPLETON INC | 1.2M | $1.0M | 0.0% | 1.6% | 0.0% |
| 5 | BlackRock, Inc. | 935,893 | $1.1M | 0.0% | 1.2% | -3.8% |
| 6 | BLAIR WILLIAM & CO/IL | 916,975 | $1.1M | 0.0% | 1.2% | +0.5% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 839,868 | $1.0M | 0.0% | 1.1% | +2.4% |
| 8 | GoalVest Advisory LLCNEW | 687,285 | $831,615 | 0.1% | 0.9% | new |
| 9 | GSA CAPITAL PARTNERS LLP | 537,602 | $650,000 | 0.0% | 0.7% | +210.3% |
| 10 | VANGUARD FIDUCIARY TRUST CO | 476,825 | $576,958 | 0.0% | 0.6% | +16.1% |
| 11 | Balyasny Asset Management L.P.NEW | 381,940 | $462,147 | 0.0% | 0.5% | new |
| 12 | STATE STREET CORP | 324,095 | $392,155 | 0.0% | 0.4% | -2.2% |
| 13 | TWO SIGMA INVESTMENTS, LP | 321,831 | $389,416 | 0.0% | 0.4% | +575.2% |
| 14 | UBS Group AG | 300,156 | $363,188 | 0.0% | 0.4% | -53.0% |
| 15 | BNP PARIBAS FINANCIAL MARKETS | 228,289 | $276,230 | 0.0% | 0.3% | -0.1% |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 218,495 | $264,379 | 0.0% | 0.3% | +88.1% |
| 17 | X-Square Capital, LLC | 205,700 | $249,000 | 0.1% | 0.3% | 0.0% |
| 18 | MORGAN STANLEY | 180,632 | $218,564 | 0.0% | 0.2% | -26.6% |
| 19 | Bank of New York Mellon Corp | 161,689 | $195,643 | 0.0% | 0.2% | 0.0% |
| 20 | GOLDMAN SACHS GROUP INC | 155,143 | $187,723 | 0.0% | 0.2% | +28.4% |
| 21 | NORTHERN TRUST CORP | 152,875 | $184,979 | 0.0% | 0.2% | 0.0% |
| 22 | MILLENNIUM MANAGEMENT LLC | 116,375 | $140,814 | 0.0% | 0.2% | -13.5% |
| 23 | AlphaCore Capital LLC | 108,426 | $131,195 | 0.0% | 0.1% | -0.1% |
| 24 | MARSHALL WACE, LLP | 108,099 | $130,800 | 0.0% | 0.1% | -33.4% |
| 25 | JANE STREET GROUP, LLC | 78,228 | $94,655 | 0.0% | 0.1% | -87.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.